Navigation Links
Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
Date:4/12/2011

ic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Novartis has submitted marketing applications for everolimus for this use to the European Medicines Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and additional regulatory submissions are under way worldwide.

Afinitor is available in the US in 2.5 mg, 5 mg and 10 mg tablet strengths. With once-daily dosing, Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.

In the US, everolimus is available in different dosage strengths for the non-oncology patient population under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. As an investigational compound the safety and efficacy profile of everolimus has not yet been established in pancreatic or any other type of NET. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for pancreatic or any other type of NET or any additional indications anywhere in the world.

Important Safety Information for Afini
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
2. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
3. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
4. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
9. Novartis to Expand Global Research Headquarters in Cambridge, MA
10. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
11. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, ... (Hospitals), Advanced technologies - Global Forecast to 2019" ... poised to reach $19,786.3 Million by 2019 from ... 6.8% from 2014 to 2019. Browse ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Product ... Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular ... http://www.reportlinker.com/p0397058/Product-Pipeline-in-Medical-Equipment-Market---Robust-Pipeline-Strengthening-the-In-Vitro-Diagnostics-and-Cardiovascular-Devices-Market.html Product Pipeline in ...
... Ala., Feb. 17, 2011 SuccessEHS, a nationally recognized, ... EMR) software vendor, was recently named by the Arkansas ... in accordance with government health care initiatives. ... Arkansas REC are endowed by the Office of ...
Cached Medicine Technology:Reportlinker Adds Product Pipeline in Medical Equipment Market - Robust Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular Devices Market 2Arkansas REC Selects SuccessEHS as Preferred Vendor 2Arkansas REC Selects SuccessEHS as Preferred Vendor 3
(Date:9/22/2014)... FL (PRWEB) September 22, 2014 ... than 2,000 physicians, today Clearwater Clinical ... ClearSCOPE Endoscope Adaptor for smartphones. ClearSCOPE ... video from virtually any endoscope and smartphone. , ... adaptor in response to frustrations over the cost, ...
(Date:9/22/2014)... On Saturday, September 27, 2014, La Comunidad Hispana ... fair ¡Vive tu vida! Get Up! Get Moving!® This event ... health and wellness for people of all ages and all ... public, will be held at Anson B. Nixon Park, 100 ... pm. , “This is a wonderful event each year ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... six-year study of people with type 2 diabetes found ... in preventing heart attacks, strokes and deaths. But intensive ... found. For the study, investigators followed nearly 8,500 ... had their blood pressure and blood sugar levels strictly ...
(Date:9/22/2014)... September 22, 2014 At the ... nonprofit Seafood Nutrition Partnership (SNP) announced the successful ... Healthy: A Cardiovascular Risk Reduction Program for Women. ... understand and mitigate their risk of heart disease ... Action, a plan for addressing significant global challenges ...
(Date:9/22/2014)... The Drive Against Domestic Violence ( ... Ben Talei, MD - a Beverly Hills Facial Plastic ... brothers have planned to drive across the country during ... raise funds and awareness for the National Coalition Against ... the American Academy of Facial Plastic & Reconstructive Surgery's ...
Breaking Medicine News(10 mins):Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 2Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:FOX 5 News Story - Dr. Ben Talei a Beverly Hills Facial Plastic Surgeon organizes the Drive Against Domestic Violence & Botox-for-a-Cause as he Drives across the country 2Health News:FOX 5 News Story - Dr. Ben Talei a Beverly Hills Facial Plastic Surgeon organizes the Drive Against Domestic Violence & Botox-for-a-Cause as he Drives across the country 3
... Berger & Grossmann LLP is issuing the following statement regarding the Sunrise Senior Living, Inc. Securities Litigation. , , ... UNITED STATES DISTRICT COURT, ... INC. Master File, SECURITIES LITIGATION ... Relates to: All Cases, ...
... suggests, , , MONDAY, April 20 (HealthDay News) -- Want to live ... manage your stress. , A new study found that those were ... 100, and longevity is thought to run in families. , "We ... set the children of centenarians apart from other people the same ...
... HOLLYWOOD, Calif., April 20 IPC The Hospitalist ... hospitalist physician group practice company, announced today that it will ... on May 4, 2009, after the market close.A conference call ... (2:00 p.m. PT) on May 4, 2009 and will be ...
... "With Hurricanes Katrina, Rita and Ike we ... and healthcare providers navigate through chaos created by ... Davies, M.D., a seasoned critical care physician and ... which enable communication between patients, their physicians, hospitals ...
... with Picoplatin as Second-Line Therapy for Small Cell Lung ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... of its Phase 2 clinical trial of picoplatin in ... were published in the April 20, 2009, print ...
... 20, 2009 Forest Laboratories, Inc. (NYSE: FRX ... announced today that Savella(TM) (milnacipran HCl), a selective serotonin and ... will be shipped to wholesalers on April 24th and will ... Savella was approved by the U.S. Food and Drug Administration ...
Cached Medicine News:Health News:All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. ('Sunrise') Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The 'Class') 2Health News:All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. ('Sunrise') Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The 'Class') 3Health News:Outgoing Nature Could Get You to 100 2Health News:Outgoing Nature Could Get You to 100 3Health News:IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 3Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 4Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 2Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 3Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 4Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 5Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 2Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 3Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 4Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 5Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 6
... Sun Med TruFlow™ Oxygen flowmeter with a ... warranty covering calibration and manufacturing defects. A ... meet most needs. Also available with all ... power take-off and double unit configurations. Our ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: